Page 34«..1020..33343536..4050..»

Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors

By Dr. Matthew Watson

REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee.

Go here to see the original:
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors

To Read More: Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
categoriaGlobal News Feed commentoComments Off on Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors | dataApril 5th, 2023
Read All

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first…

By Dr. Matthew Watson

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies today announced that the Company entered into the warrant agreement (the “Warrant Agreement”) and finalized the related ancillary documents required under the credit facility with the European Investment Bank (“EIB”) (the "Finance Contract") for up to €40 million previously announced on December 28, 2022. The Company also announced the drawdown of the first tranche of €20 million (“Tranche A”) under the Finance Contract, expected to be disbursed by the EIB in early April 2023. The Company plans to use the proceeds of Tranche A towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.

More:
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first...

To Read More: Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first…
categoriaGlobal News Feed commentoComments Off on Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first… | dataApril 5th, 2023
Read All

Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

By Dr. Matthew Watson

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike in addition to other viral genes of SARS-CoV-2. The program aims to serve as proof-of-concept for Gritstone’s infectious disease vaccine approach and the potential application of samRNA against infectious diseases.

See original here:
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

To Read More: Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
categoriaGlobal News Feed commentoComments Off on Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023 | dataApril 5th, 2023
Read All

INTERNATIONAL STEM CELL CORP MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com

By daniellenierenberg

INTERNATIONAL STEM CELL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)  Marketscreener.com

View post:
INTERNATIONAL STEM CELL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

To Read More: INTERNATIONAL STEM CELL CORP MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com
categoriaSkin Stem Cells commentoComments Off on INTERNATIONAL STEM CELL CORP MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com | dataApril 5th, 2023
Read All

Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023

By Dr. Matthew Watson

Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") in the meeting room ‘Jónas Einarsson auditorium’ in Ullernchausséen 64, 0379 Oslo, at 14:00 CET on 20 April 2023.

Go here to read the rest:
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023

To Read More: Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
categoriaGlobal News Feed commentoComments Off on Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023 | dataMarch 25th, 2023
Read All

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

By Dr. Matthew Watson

NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

Read this article:
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

To Read More: atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
categoriaGlobal News Feed commentoComments Off on atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights | dataMarch 25th, 2023
Read All

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

Read more:
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

To Read More: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update | dataMarch 25th, 2023
Read All

Grace Breeding Reports 2022 Full-Year Financial Results

By Dr. Matthew Watson

- Program developments throughout 2022, and, to date in 2023, bring Grace Breeding closer to offering crop solutions to farmers aligned with environmental responsibility and reversing climate change -

View original post here:
Grace Breeding Reports 2022 Full-Year Financial Results

To Read More: Grace Breeding Reports 2022 Full-Year Financial Results
categoriaGlobal News Feed commentoComments Off on Grace Breeding Reports 2022 Full-Year Financial Results | dataMarch 25th, 2023
Read All

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

By Dr. Matthew Watson

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers

Read the original:
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

To Read More: 23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
categoriaGlobal News Feed commentoComments Off on 23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease | dataMarch 25th, 2023
Read All

Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

By Dr. Matthew Watson

-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients

Read more:
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

To Read More: Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
categoriaGlobal News Feed commentoComments Off on Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update | dataMarch 25th, 2023
Read All

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

By Dr. Matthew Watson

ANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported fourth quarter and full year 2022 financial results and provided an update on its business.

Follow this link:
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

To Read More: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
categoriaGlobal News Feed commentoComments Off on Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates | dataMarch 25th, 2023
Read All

Abeona Therapeutics Announces New Employee Inducement Grants

By Dr. Matthew Watson

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona.

Read more from the original source:
Abeona Therapeutics Announces New Employee Inducement Grants

To Read More: Abeona Therapeutics Announces New Employee Inducement Grants
categoriaGlobal News Feed commentoComments Off on Abeona Therapeutics Announces New Employee Inducement Grants | dataMarch 25th, 2023
Read All

Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

By Dr. Matthew Watson

Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization

See the original post:
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

To Read More: Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update | dataMarch 25th, 2023
Read All

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

By Dr. Matthew Watson

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Continue reading here:
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

To Read More: Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
categoriaGlobal News Feed commentoComments Off on Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference | dataMarch 25th, 2023
Read All

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

By Dr. Matthew Watson

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company’s progress.

See the original post:
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

To Read More: Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
categoriaGlobal News Feed commentoComments Off on Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments | dataMarch 25th, 2023
Read All

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

By Dr. Matthew Watson

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022

See the article here:
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

To Read More: Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update | dataMarch 25th, 2023
Read All

Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics

By Dr. Matthew Watson

Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton

Here is the original post:
Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics

To Read More: Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics
categoriaGlobal News Feed commentoComments Off on Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics | dataMarch 25th, 2023
Read All

Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER…

By Dr. Matthew Watson

Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg and 50 mg doses versus the 14 mg dose of oral semaglutide.

Link:
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER...

To Read More: Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER…
categoriaGlobal News Feed commentoComments Off on Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER… | dataMarch 25th, 2023
Read All

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA

By Dr. Matthew Watson

Regulated Information - Denominator

See the article here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA

To Read More: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA
categoriaGlobal News Feed commentoComments Off on Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA | dataMarch 25th, 2023
Read All

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

By Dr. Matthew Watson

HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.

Read the original:
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

To Read More: Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
categoriaGlobal News Feed commentoComments Off on Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 | dataMarch 25th, 2023
Read All

Page 34«..1020..33343536..4050..»


Copyright :: 2024